Get the Stockscreener App
0.6058
0.69%
-0.0042
Citius Oncology Inc Stock (CTOR) Latest News
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - Simply Wall St
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financia - GuruFocus.com
Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN
Citius Oncology (NASDAQ:CTOR) Issues Earnings Results - MarketBeat
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - 69News WFMZ-TV
Citius Oncology Inc. (CTOR) reports earnings - Quartz
CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds - StockTitan
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan
Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World
Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria
Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan
Citius Oncology (NASDAQ:CTOR) Shares Down 2%Here's What Happened - MarketBeat
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - 69News WFMZ-TV
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - BioSpace
Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire
Citius Oncology to explore strategic alternatives - Yahoo Finance
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve
Citius Oncology Explores Strategic Options with Jefferies Following LYMPHIR FDA Approval - StockTitan
Citius Pharma Reports 2024 Financial Results and Business Update - MSN
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance
Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz
Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com
Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart
“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch” - Financial Content
Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World
Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com
Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan
CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada
CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
0.85%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):